Spruce Biosciences, Inc.
SPRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001683553
No open-market purchases or sales by Spruce Biosciences, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $116.3M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Spruce Biosciences, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 41 | 40 | −1 |
| Shares | 31.9M | 32.3M | +369.4K (+1.2%) |
| Value | $72.0M | $94.4M | +$22.4M (+31.1%) |
New holders (4)
Institutions that held Spruce Biosciences, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Rosalind Advisors, Inc. | 1,586,392 | $4.65M | 3.89% |
| Superstring Capital Management LP | 118,814 | $348.1K | 0.25% |
| Marshall Wace, LLP | 105,721 | $309.8K | 0.00% |
| Qube Research & Technologies Ltd | 2 | $6 | 0.00% |
Sold out (5)
Institutions that held Spruce Biosciences, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Verition Fund Management LLC | 1,319,393 | $2.98M |
| Bank of New York Mellon Corp | 89,120 | $201.4K |
| Dimensional Fund Advisors LP | 32,452 | $73.3K |
| Tower Research Capital LLC (TRC) | 4,356 | $9.85K |
| FMR LLC | 36 | $82 |